Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response
MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response